EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
|
1.3B USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
932.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
271B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
236.2B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.8B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
287.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
153.8B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
EyePoint Pharmaceuticals Inc
Glance View
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Watertown, Massachusetts and currently employs 122 full-time employees. The company went IPO on 2005-01-27. The Company’s lead product candidate, EYP-1901, combines a bioerodible formulation of its Durasert technology with vorolanib, a tyrosine kinase inhibitor (TKI), which has demonstrated anti-VEGF activity. The firm has two commercial products, YUTIQ and DEXYCU. YUTIQ is a non-erodible intravitreal implant containing fluocinolone acetonide (FA) lasting for up to 36 months and is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. YUTIQ utilizes its Durasert sustained-release drug delivery technology platform. DEXYCU is an indicated for the treatment of post-operative ocular inflammation. DEXYCU utilizes its Verisome drug-delivery technology. The firm is also advancing YUTIQ 50, a six-month treatment for non-infectious uveitis affecting the posterior segment of the eye, one of the causes of blindness under a supplemental new drug application (sNDA) strategy.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for EyePoint Pharmaceuticals Inc is 93.4%, which is above its 3-year median of 89.7%.
Over the last 3 years, EyePoint Pharmaceuticals Inc’s Gross Margin has increased from 79.9% to 93.4%. During this period, it reached a low of 79.9% on Dec 31, 2022 and a high of 95.1% on Jun 30, 2025.
